Clinical Trial

Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A phase Ⅱ open label multi-cencter clinical trail to evaluate the efficacy and safety of pembrolizumab combined with low-dose PF (cisplatin + 5-fluorouracil) in the neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-06-30; most recent amendment 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2022-12-26
Trial Details
NCT Number NCT05446467
Lead Sponsor Zhejiang Provincial People's Hospital
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 80 participants
Start Date 2022-09-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-20